Application of Machine Learning for Predicting Progression‐Free and Overall Survival in Patients With Renal Cell Carcinoma
Clinical and Translational Science · 2025-10 · 18 (10)
DOI: 10.1111/cts.70348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 23.10.2025. Verfasst von Caroline W Grant und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Machine Learning, Kidney Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Patient outcomes in advanced renal cell carcinoma (RCC) remain poor, with five‐year survival rates ranging from ~10% to 30%. Early projections of therapeutic outcomes could optimize precision medicine and accelerate drug development. While machine learning (ML) models integrating tumor growth inhibition (TGI) metrics have improved survival predictions over traditional models, their application in RCC remains unexplored. Herein, we used TGI metrics and baseline data to evaluate parametric (PM) and semi‐parametric (SPM) survival models alongside ML approaches for predicting progression‐free (PFS) and overall survival (OS) in 1839 RCC patients from four trials (evaluating sunitinib, axitinib, sorafenib, interferon‐alpha, and avelumab + axitinib). Data were split into training (70%) and testing (30%), and feature selection was used to determine parsimonious and robust models. Bootstrap resampling ( n = 100) was employed for models' validation, and performance was assessed using C‐index and Integrated Brier Score. In brief, training data results demonstrated that tree‐based ML models (random survival forest (RSF) and XGBoost) outperformed PM and SPM models in predicting PFS (C‐index: 0.783–0.785 vs. 0.725–0.738 for PM and SPM; p < 0.05) and OS (C‐index: 0.77–0.867 vs. 0.750–0.758 for PM and SPM; p < 0.05), with RSF achieving better prediction of PFS and OS using only 3–5 covariates, compared to 9–35 with other tested methods. Tree‐based methods were also superior in the testing data. SHapley Additive exPlanations revealed nonlinear relationships among top predictors, including TGI metrics, underscoring the ability of tree‐based methods to capture complex prognostic interactions. Further validation is required to confirm models' generalizability to additional therapies and patients with differing tumor severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
- Clinical Pharmacology, Pfizer Inc., New York, New York, USA.
- Clinical Pharmacology, Neurocrine Biosciences, San Diego, California, USA.
- Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, Spring House, Pennsylvania, USA.
- Pfizer Research and Development, Pfizer Inc., Groton, Connecticut, USA.
ORCID-Profile: Caroline W Grant, Jerry Li, Swan Lin, Daniele Ouellet, Mohamed H Shahin
Zitieren
APA
Grant, C. W., Li, J., Lin, S., Nickens, D., Ouellet, D., & Shahin, M. H. (2025). Application of Machine Learning for Predicting Progression‐Free and Overall Survival in Patients With Renal Cell Carcinoma. Clinical and Translational Science, 18(10). https://doi.org/10.1111/cts.70348
Vancouver
Grant CW, Li J, Lin S, Nickens D, Ouellet D, Shahin MH. Application of Machine Learning for Predicting Progression‐Free and Overall Survival in Patients With Renal Cell Carcinoma. Clinical and Translational Science. 2025;18(10). doi:10.1111/cts.70348
BibTeX
@article{Grant2025,
author = {Grant, Caroline W and Li, Jerry and Lin, Swan and Nickens, Dana and Ouellet, Daniele and Shahin, Mohamed H},
title = {Application of Machine Learning for Predicting Progression‐Free and Overall Survival in Patients With Renal Cell Carcinoma},
journal = {Clinical and Translational Science},
year = {2025},
volume = {18},
number = {10},
doi = {10.1111/cts.70348}
}
EUVIMED